In situ hydrogel enhances non-efferocytic phagocytosis for post-surgical tumor treatment

J Control Release. 2023 Nov:363:402-414. doi: 10.1016/j.jconrel.2023.09.041. Epub 2023 Sep 30.

Abstract

Post-surgical efferocytosis of tumor associated macrophages (TAMs) originates an immunosuppressive tumor microenvironment and facilitates abscopal metastasis of residual tumor cells. Currently, few strategies could inhibit efferocytosis while recovering the tumor-eliminative phagocytosis of TAMs. Herein, we developed an in situ hydrogel that contains anti-CD47 antibody (aCD47) and apocynin (APO), an inhibitor of nicotinamide adenine dinucleotide phosphate oxidase. This hydrogel amplifies the non-efferocytic phagocytosis of TAMs by (1) blocking the extracellular "Don't eat me" signal of efferocytosis with aCD47, which enhances the receptor-mediated recognition and engulfment of tumor cells by TAMs in the post-surgical tumor bed, and (2) by utilizing APO to dispose of tumor debris in a non-efferocytic manner, which prevents acidification and maturation of efferosomes and allows for M1-polarization of TAMs, leading to improved antigen presentation ability. With the complementary intervention of extracellular and intracellular, this hydrogel reverses the immunosuppressive effects of efferocytosis, and induces a potent M1-associated Th1 immune response against tumor recurrence. In addition, the in situ detachment and distal colonization of metastatic tumor cells were efficiently restrained due to the intervention of efferocytosis. Collectively, the hydrogel potentiates surgery treatment of tumor by recovering the tumor-elimination ability of post-surgical TAMs.

Keywords: Efferocytosis; In situ hydrogel; Phagocytosis; Post-surgical tumor treatment; Th1; Tumor associated macrophages.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Hydrogels / pharmacology
  • Macrophages*
  • Neoplasms* / pathology
  • Phagocytosis
  • Tumor Microenvironment

Substances

  • Hydrogels